Abbott Labs (ABT) PT Lowered to $122 at Wells Fargo

Wells Fargo analyst Larry Biegelsen lowered the price target on Abbott Labs (NYSE: ABT) to $122.00 (from $146.00) while maintaining a Overweight rating.

The analyst comments "On 1/22, ABT reported a Q4 sales miss and in-line EPS on transitory headwinds (largely in Nutrition). 2026 organic sales growth guidance of 6.5-7.5% is below prior consensus due to Nutrition headwinds persisting into 1H '26. EPS guide was in line. Q4 sales of $11.6B below Street/our est. $11.8B on 1x items. Q4 org sales of +3.8% missed our 7.0% est (ex-COVID testing), due to transitory issues in Nutrition (pricing action), Rapid Dx (delayed flu season), and Libre (OUS recall). Beyond Nutrition, all segments other than EPD slightly missed our estimates."

You May Also Be Interested In

• Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Aurora Spine settles patent dispute, secures $600K insider loan